Literature DB >> 19287187

Myocardial infarction patients show altered lipoprotein properties and functions when compared with stable angina pectoris patients.

Kyung-Hyun Cho1, Dong-Gu Shin, Suk-Hwan Baek, Jae-Ryong Kim.   

Abstract

Several parameters and risk factors were compared between Korean male myocardial infarction (MI) patients (n=10) and angina pectoris (AP) patients (n=17) to search unique biomarkers for myocardial infarction (MI) in lipoprotein level. Individual serum and lipoprotein fractions (VLDL, LDL, HDL2, HDL3) were isolated and analyzed by lipid and protein determination and enzyme assay. The MI group was found to have a 25 and 30% higher serum cholesterol and triacylglycerol (TG) level than the AP group, respectively, however, their body mass index (BMI), LDL-cholesterol (C), HDL-C, and glucose levels fell within the normal range. MI patients were found to have an approximately two-fold higher level of serum IL-6 and an 18% lower serum apoA-I level than that of the AP group. LDL and HDL2 fraction of the MI group were more enriched with TG than those of AP group. The increased TG was correlated well with the increased level of apoC-III in the same fraction. Cholesteryl ester transfer protein (CETP) activity and protein level were greatly increased in MI patients in the LDL and HDL3 fractions. MI patients showed more severely oxidized LDL fraction than patients in the AP group, as well as the weakest antioxidant ability of serum. Conclusively, MI patients were found to have unique serum and lipoprotein characteristics including increased IL-6 and TG in serum, with CETP and apoC-III in the LDL and HDL fractions, as well as severely impaired antioxidant ability of HDL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19287187      PMCID: PMC2679332          DOI: 10.3858/emm.2009.41.2.009

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  30 in total

1.  It's time for a change to a troponin standard.

Authors:  A S Jaffe; J Ravkilde; R Roberts; U Naslund; F S Apple; M Galvani; H Katus
Journal:  Circulation       Date:  2000-09-12       Impact factor: 29.690

2.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

3.  Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes.

Authors:  S Ehara; M Ueda; T Naruko; K Haze; A Itoh; M Otsuka; R Komatsu; T Matsuo; H Itabe; T Takano; Y Tsukamoto; M Yoshiyama; K Takeuchi; J Yoshikawa; A E Becker
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

4.  The human serum paraoxonase/arylesterase polymorphism.

Authors:  H W Eckerson; C M Wyte; B N La Du
Journal:  Am J Hum Genet       Date:  1983-11       Impact factor: 11.025

5.  N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2.

Authors:  H F Boyd; S C Fell; S T Flynn; D M Hickey; R J Ife; C A Leach; C H Macphee; K J Milliner; K E Moores; I L Pinto; R A Porter; D A Rawlings; S A Smith; I G Stansfield; D G Tew; C J Theobald; C M Whittaker
Journal:  Bioorg Med Chem Lett       Date:  2000-11-20       Impact factor: 2.823

6.  Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region.

Authors:  A Patel; F Barzi; K Jamrozik; T H Lam; H Ueshima; G Whitlock; M Woodward
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

7.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.

Authors:  C J Packard; D S O'Reilly; M J Caslake; A D McMahon; I Ford; J Cooney; C H Macphee; K E Suckling; M Krishna; F E Wilkinson; A Rumley; G D Lowe
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

8.  VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial.

Authors:  F M Sacks; P Alaupovic; L A Moye; T G Cole; B Sussex; M J Stampfer; M A Pfeffer; E Braunwald
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

9.  Low-density lipoprotein subclass patterns and risk of myocardial infarction.

Authors:  M A Austin; J L Breslow; C H Hennekens; J E Buring; W C Willett; R M Krauss
Journal:  JAMA       Date:  1988-10-07       Impact factor: 56.272

10.  Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Christie M Ballantyne; Ron C Hoogeveen; Heejung Bang; Josef Coresh; Aaron R Folsom; Gerardo Heiss; A Richey Sharrett
Journal:  Circulation       Date:  2004-02-02       Impact factor: 29.690

View more
  9 in total

1.  Safety and Tolerability of ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose Escalation Study.

Authors:  Robert D Shamburek; Rebecca Bakker-Arkema; Alexandra M Shamburek; Lita A Freeman; Marcelo J Amar; Bruce Auerbach; Brian R Krause; Reynold Homan; Steve J Adelman; Heidi L Collins; Maureen Sampson; Anna Wolska; Alan T Remaley
Journal:  Circ Res       Date:  2015-12-01       Impact factor: 17.367

2.  Females with angina pectoris have altered lipoprotein metabolism with elevated cholesteryl ester transfer protein activity and impaired high-density lipoproteins-associated antioxidant enzymes.

Authors:  Jungho Park; Jae-Ryong Kim; Dong-Gu Shin; Kyung-Hyun Cho
Journal:  Int J Mol Med       Date:  2011-12-29       Impact factor: 4.101

3.  Altered lipoproteins in patients with systemic lupus erythematosus are associated with augmented oxidative stress: a potential role in atherosclerosis.

Authors:  Jin Kyun Park; Jae-Yong Kim; Jin Young Moon; Eun Young Ahn; Eun Young Lee; Eun Bong Lee; Kyung-Hyun Cho; Yeong Wook Song
Journal:  Arthritis Res Ther       Date:  2016-12-30       Impact factor: 5.156

4.  Consumption of policosanol enhances HDL functionality via CETP inhibition and reduces blood pressure and visceral fat in young and middle-aged subjects.

Authors:  Jae-Yong Kim; Seong-Min Kim; Suk-Jeong Kim; Eun-Young Lee; Jae-Ryong Kim; Kyung-Hyun Cho
Journal:  Int J Mol Med       Date:  2017-02-24       Impact factor: 4.101

5.  Cuban Sugar Cane Wax Acid and Policosanol Showed Similar Atheroprotective Effects with Inhibition of LDL Oxidation and Cholesteryl Ester Transfer via Enhancement of High-Density Lipoproteins Functionality.

Authors:  Kyung-Hyun Cho; Myung-Ae Bae; Jae-Ryong Kim
Journal:  Cardiovasc Ther       Date:  2019-02-24       Impact factor: 3.023

6.  Anti-Atherosclerotic Effects of Fruits of Vitex rotundifolia and Their Isolated Compounds via Inhibition of Human LDL and HDL Oxidation.

Authors:  Jae-Yong Kim; Sang Hee Shim
Journal:  Biomolecules       Date:  2019-11-12

7.  Native High-Density Lipoproteins (HDL) with Higher Paraoxonase Exerts a Potent Antiviral Effect against SARS-CoV-2 (COVID-19), While Glycated HDL Lost the Antiviral Activity.

Authors:  Kyung-Hyun Cho; Jae-Ryong Kim; In-Chul Lee; Hyung-Jun Kwon
Journal:  Antioxidants (Basel)       Date:  2021-02-01

8.  Blood Pressure Lowering Effect of Cuban Policosanol is Accompanied by Improvement of Hepatic Inflammation, Lipoprotein Profile, and HDL Quality in Spontaneously Hypertensive Rats.

Authors:  Kyung-Hyun Cho; Dhananjay Yadav; Suk-Jeong Kim; Jae-Ryong Kim
Journal:  Molecules       Date:  2018-05-03       Impact factor: 4.411

9.  Slim Body Weight Is Highly Associated With Enhanced Lipoprotein Functionality, Higher HDL-C, and Large HDL Particle Size in Young Women.

Authors:  Ki-Hoon Park; Dhananjay Yadav; Suk-Jeong Kim; Jae-Ryong Kim; Kyung-Hyun Cho
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-19       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.